In reality, they differ in FDA-approved uses, dosing ranges, clinical trial data, and insurance coverage
Expectations from phase 2 were pointing towards 14-15% weight loss vs 11.2%, but this is why we perform clinical trials
Renal function should be monitored, especially if patients experience significant gastrointestinal symptoms that could lead to dehydration
For tirzepatide versus semaglutide, contrary to the primary endpoint in the head-to-head comparison, there was some supporting evidence for tirzepatide to have a modest benefit, although the 95% CI overlapped the null (HR 0.91, 95% CI 0.81 to 1.01) (Fig
BMI 35 to 40: Expect to reach 6 to 10 mg daily before seeing the consistent, sustained weight loss that compounds into significant results over months